Gufic BioSciences
283.20
-11.15(-3.79%)
Market Cap₹2,840.00 Cr
PE Ratio59.03
IndustryHealthcare
Company Performance:
1D-3.79%
1M-1.85%
6M-23.45%
1Y-17.82%
5Y+164.18%
View Company Insightsright
More news about Gufic BioSciences
30May 25
Gufic Biosciences Reports Mixed Q4 Results: Revenue Up, Profits Down
Gufic Biosciences' Q4 financial results show a 5.13% increase in revenue to ₹2.05 billion, but a significant decline in profitability. EBITDA fell to ₹266.00 million from ₹342.30 million year-over-year, with EBITDA margin dropping to 12.99% from 17.55%. Net profit sharply decreased to ₹80.00 million from ₹200.00 million in the previous year. The company faces challenges in maintaining profit margins despite revenue growth.
 no imag found
Gufic BioSciences
283.20
-11.15
(-3.79%)
1 Year Returns:-17.82%
Industry Peers
Sun Pharmaceutical
1,766.00
(-0.62%)
Divis Laboratories
6,003.00
(-1.59%)
Torrent Pharmaceuticals
4,202.60
(-1.58%)
Dr Reddys Laboratories
1,273.30
(-1.97%)
Lupin
2,300.30
(-0.96%)
Cipla
1,235.60
(-1.66%)
Zydus Life Science
871.25
(-2.16%)
Mankind Pharma
1,921.30
(-3.94%)
Aurobindo Pharma
1,275.50
(-1.23%)
Alkem Laboratories
5,153.00
(-1.99%)